ArticleJournal of affective disorders2016
Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer.
Article in Journal of affective disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Effect of traditional Chinese medicine on postoperative depression of breast cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Evidence of brain-derived neurotrophic factor in ameliorating cancer-related cognitive impairment: A systematic review of human studies.Critical reviews in oncology/hematology · 2022Pooled it
- Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy.Molecular neurobiology · 2019Pooled it
- Systematic review of genetic polymorphisms associated with psychoneurological symptoms in breast cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Pooled it
- Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]).Translational behavioral medicine · 2019Trial
- Cognitive changes associated with chemotherapy in breast cancer: an assessment of social cognition and executive functions in Peruvian patients.The oncologist · 2026Article
- Exploring the Association Between DTC Obesity-Related Gene Polymorphisms and Obesity Risk Factors in Koreans: Focus onNutrients · 2026Article
- Dysregulated Neuroimmune and Anhedonia-Like Behavioral Response Following Peripheral Immune Challenge in Mice Carrying the Val66Met Brain-Derived Neurotrophic Factor Polymorphism.Psychiatry international · 2025Article
- Construction of a nomogram-based risk prediction model for depressive symptoms in middle-aged and young breast cancer patients.World journal of clinical oncology · 2025Article
- Physical Activity and Depression in Breast Cancer Patients: Mechanisms and Therapeutic Potential.Current oncology (Toronto, Ont.) · 2025Review
- Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.The pharmacogenomics journal · 2024Article
- Elevated neopterin and decreased IL-4, BDNF levels and depression in lymphoma patients receiving R-CHOP chemotherapy.Frontiers in neurology · 2024Article
- Interactions of BDNF Val66met and dietary indices in relation to metabolic markers among patient with type 2 diabetes mellitus: a cross-sectional study.Journal of health, population, and nutrition · 2023Article
- Brain-derived neurotrophic factor and inflammation in depression: Pathogenic partners in crime?World journal of psychiatry · 2022Review
- Association of genetic polymorphisms with psychological symptoms in cancer: A systematic review.Asia-Pacific journal of oncology nursing · 2022Review
- Mechanisms of Chemotherapy-Induced Neurotoxicity.Frontiers in pharmacology · 2022Review
- Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment.Cytokine · 2021Article
- Childhood maltreatment history and attention bias variability in healthy adult women: role of inflammation and the BDNF Val66Met genotype.Translational psychiatry · 2021Article
- Changes and Influencing Factors of Cognitive Impairment in Patients with Breast Cancer.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Characteristics and subtypes of depressive symptoms in Chinese female breast cancer patients of different ages: a cross-sectional study.AIMS public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundInflammation contributes to the development of depression in a subset of individuals, but risk factors that render certain individuals particularly vulnerable to inflammation-associated depression are undetermined. Drawing from animal studies showing that reduced neuroplasticity mediates effects of inflammation on depression, we hypothesized that individuals genetically predisposed to lower levels of neuroplasticity would be more susceptible to inflammation-associated depression. The current study examined whether the Met allele of the BDNF Val66met polymorphism, which predisposes individuals to reduced levels of brain-derived neurotrophic factor (BDNF), a protein vital for neuroplasticity, moderates the association between inflammation and depressive symptoms.
methodsOur sample was 112 women with early-stage breast cancer who had recently completed cancer treatment, which can activate inflammation. Participants provided blood for genotyping and assessment of circulating inflammatory markers, and completed a questionnaire assessing depressive symptoms, including somatic, affective, and cognitive dimensions.
resultsThere was a significant interaction between C-reactive protein (CRP) and the BDNF Val66met polymorphism in predicting cognitive depressive symptoms (p=.004), such that higher CRP was related to more cognitive depressive symptoms among Met allele carriers, but not among Val/Val homozygotes. Post-hoc longitudinal analyses suggested that, for Met carriers, higher CRP at baseline predicted higher cognitive depressive symptoms across a one-year follow-up period (p<.001).
conclusionThe BDNF Met allele may be a risk factor for inflammation-associated cognitive depressive symptoms among breast cancer survivors. Women with breast cancer who carry this genotype may benefit from early identification and treatment. LIMITATION: BDNF genotype is an indirect measure of BDNF protein levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.